Somatostatin receptors: From signaling to clinical practice

Frontiers in Neuroendocrinology

Volumn 34, Issue 3, 2013, Pages 228-252

  Theodoropoulou, Marily ^a   Stalla, Günter K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Dopastatin; MTOR; Neuroendocrine tumor; Octreotide; Pasireotide; Pituitary; Proliferation; Signal transduction; Somatostatin; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; ANTIMITOTIC AGENT; BIM 23 A 387; DOPASTATIN; OCTREOTIDE; PASIREOTIDE; SOMATOPRIM; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ACROMEGALY; ACTH SECRETING ADENOMA; ADRENAL TUMOR; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CLINICAL PRACTICE; CUSHING DISEASE; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; HOT FLUSH; HUMAN; HYPOPHYSIS ADENOMA; MOLECULAR DYNAMICS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; THYROTROPIN SECRETING ADENOMA; UPREGULATION;

EID: 84881316730     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2013.07.005     Document Type: Review

References (436)

1. Acunzo J., Thirion S., Roche C., Saveanu A., Gunz G., Germanetti A.L., Couderc B., Cohen R., Figarella-Branger D., Dufour H., Brue T., Enjalbert A., Barlier A. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res. 2008, 68:10163-10170.
2. Afargan M., Janson E.T., Gelerman G., Rosenfeld R., Ziv O., Karpov O., Wolf A., Bracha M., Shohat D., Liapakis G., Gilon C., Hoffman A., Stephensky D., Oberg K. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001, 142:477-486.
3. Aguilera G., Harwood J.P., Catt K.J. Somatostatin modulates effects of angiotensin II in adrenal glomerulosa zone. Nature 1981, 292:262-263.
4. Ahrendt S.A., Mcguire G.E., Pitt H.A., Lillemoe K.D. Why does somatostatin cause gallstones. Am. J. Surg. 1991, 161:177-183.
5. 2+ mobilization by cloned human somatostatin receptor subtypes-1-5, in ransfected COS-7 cells. FEBS Lett. 1994, 348:192-196.
6. Alberti K.G., Christensen N.J., Christensen S.E., Hansen A.P., Iversen J., Lundbaek K., Seyer-Hansen K., Orskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973, 10:1299-1301.
7. Albini A., Florio T., Giunciuglio D., Masiello L., Carlone S., Corsaro A., Thellung S., Cai T., Noonan D.M., Schettini G. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 1999, 13:647-655.
8. Amato G., Mazziotti G., Rotondi M., Iorio S., Doga M., Sorvillo F., Manganella G., Di Salle F., Giustina A., Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin. Endocrinol. 2002, 56:65-71.
9. Annamalai A.K., Webb A., Kandasamy N., Elkhawad M., Moir S., Khan F., Maki-Petaja K., Gayton E.L., Strey C.H., O'Toole S., Ariyaratnam S., Halsall D.J., Chaudhry A.N., Berman L., Scoffings D.J., Antoun N.M., Dutka D.P., Wilkinson I.B., Shneerson J.M., Pickard J.D., Simpson H.L., Gurnell M. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metabol. 2013, 98:1040-1050.
10. Anthony L., Freda P.U. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr. Med. Res. Opin. 2009, 25:2989-2999.
11. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur. J. Nucl. Med. Mol. Imag. 2007, 34:982-993.
12. Aparicio T., Ducreux M., Baudin E., Sabourin J.C., De Baere T., Mitry E., Schlumberger M., Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer 2001, 37:1014-1019.
13. Arena S., Pattarozzi A., Corsaro A., Schettini G., Florio T. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol. Endocrinol. 2005, 19:255-267.
14. Arena S., Pattarozzi A., Massa A., Esteve J.P., Iuliano R., Fusco A., Susini C., Florio T. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phosphotyrosine phosphatase eta. Mol. Endocrinol. 2007, 21:229-246.
15. Arnold R., Rinke A., Klose K.J., Muller H.H., Wied M., Zamzow K., Schmidt C., Schade-Brittinger C., Barth P., Moll R., Koller M., Unterhalt M., Hiddemann W., Schmidt-Lauber M., Pavel M., Arnold C.N. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol. 2005, 3:761-771.
16. Arvigo M., Gatto F., Ruscica M., Ameri P., Dozio E., Albertelli M., Culler M.D., Motta M., Minuto F., Magni P., Ferone D. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J. Endocrinol. 2010, 207:309-317.
17. Ayuk J., Stewart S.E., Stewart P.M., Sheppard M.C. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. 2004, 60:375-381.
18. Azar R., Najib S., Lahlou H., Susini C., Pyronnet S. Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell. Mol. Life Sci. 2008, 65:3110-3117.
19. Bajetta E., Procopio G., Ferrari L., Martinetti A., Zilembo N., Catena L., Alu M., la Torre S., Alberti D., Buzzoni R. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002, 94:299-304.
20. Baldelli R., Battista C., Leonetti F., Ghiggi M.R., Ribaudo M.C., Paoloni A., D'Amico E., Ferretti E., Baratta R., Liuzzi A., Trischitta V., Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. 2003, 59:492-499.
21. Ballare E., Persani L., Lania A.G., Filopanti M., Giammona E., Corbetta S., Mantovani S., Arosio M., Beck-Peccoz P., Faglia G., Spada A. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metabol. 2001, 86:3809-3814.
22. Barbieri F., Pattarozzi A., Gatti M., Porcile C., Bajetto A., Ferrari A., Culler M.D., Florio T. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 2008, 149:4736-4746.
23. Barbieri F., Bajetto A., Pattarozzi A., Gatti M., Würth R., Thellung S., Corsaro A., Villa V., Nizzari M., Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int. J. Pept. 2013, 2013:926295.
24. Barlier A., Gunz G., Zamora A.J., Morange-Ramos I., Figarella-Branger D., Dufour H., Enjalbert A., Jaquet P. Pronostic and therapeutic consequences of G(s)alpha mutations in somatotroph adenomas. J. Clin. Endocrinol. Metabol. 1998, 83:1604-1610.
25. Barlier A., Pellegrini-Bouiller I., Gunz G., Zamora A.J., Jaquet P., Enjalbert A. Impact of gsp oncogene on the expression of genes coding for G(s)alpha, Pit-1, G(i)2 alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J. Clin. Endocrinol. Metabol. 1999, 84:2759-2765.
26. Batista D.L., Zhang X., Gejman R., Ansell P.J., Zhou Y.L., Johnson S.A., Swearingen B., Hedley-Whyte E.T., Stratakis C.A., Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metabol. 2006, 91:4482-4488.
27. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T.J., Pless J. SMS 201-995 - a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci. 1982, 31:1133-1140.
28. Beck Peccoz P., Mariotti S., Guillausseau P.J., Medri G., Piscitelli G., Bertoli A., Barbarino A., Rondena M., Chanson P., Pinchera A., Faglia G. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J. Clin. Endocrinol. Metabol. 1989, 68:208-214.
29. Benali N., Cordelier P., Calise D., Pages P., Rochaix P., Nagy A., Esteve J.P., Pour P.M., Schally A.V., Vaysse N., Susini C., Buscail L. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9180-9185.
30. Betzel T., Hess T., Waser B., Reubi J.C., Roesch F. Closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT. Bioconjug. Chem. 2008, 19:1796-1802.
31. Bevan J.S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metabol. 2005, 90:1856-1863.
32. Bevan J.S., Atkin S.L., Atkinson A.B., Bouloux P.M., Hanna F., Harris P.E., James R.A., McConnell M., Roberts G.A., Scanlon M.F., Stewart P.M., Teasdale E., Turner H.E., Wass J.A.H., Wardlaw J.M. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metabol. 2002, 87:4554-4563.
33. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary-tumor shrinkage. Endocr. Rev. 1992, 13:220-240.
34. Bhayana S., Booth G.L., Asa S.L., Kovacs K., Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metabol. 2005, 90:6290-6295.
35. Bito H., Mori M., Sakanaka C., Takano T., Honda Z., Gotoh Y., Nishida E., Shimizu T. Functional coupling of Sstr4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release, and activation of the mitogen-activated protein kinase cascade. J. Biol. Chem. 1994, 269:12722-12730.
36. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
37. Blaker M., Schmitz M., Gocht A., Burghardt S., Schulz M., Broring D.C., Pace A., Greten H., de Weerth A. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J. Hepatol. 2004, 41:112-118.
38. Bloom S.R., Mortimer C.H., Thorner M.O., Besser G.M., Hall R., Gomez-Pan A., Roy V.M., Russell R.C.G., Coy D.H., Kastin A.J., Schally A.V. Inhibition of gastrin and gastric acid secretion by growth hormone release inhibiting hormone. Lancet 1974, 2:1106-1109.
39. Bocci G., Culler M.D., Fioravanti A., Orlandi P., Fasciani A., Colucci R., Taylor J.E., Sadat D., Danesi R., Del Tacca M. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur. J. Clin. Invest. 2007, 37:700-708.
40. Boden G., Ryan I.G., Eisenschmid B.L., Shelmet J.J., Owen O.E. Treatment of inoperable glucagonoma with the long-acting somatostatin analog SMS 201-995. N. Eng. J. Med. 1986, 314:1686-1689.
41. Boden G., Sivitz M.C., Owen O.E., Essakoumar N., Landor J.H. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1975, 190:163-165.
42. Boscaro M., Ludlam W.H., Atkinson B., Glusman J.E., Petersenn S., Reincke M., Snyder P., Tabarin A., Biller B.M.K., Findling J., Melmed S., Darby C.H., Hu K., Wang Y., Freda P.U., Grossman A.B., Frohman L.A., Bertherat J. Treatment of pituitary dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metabol. 2009, 94:115-122.
43. Boscaro M., Zhang Y., Sen K., Maldonado M., Schoenherr U., Findling J.W. Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study. Endocr. Rev. 2010, 31(3 Suppl. 1):S333. (abst P1-274).
44. Bousquet C., Delesque N., Lopez F., Saint-Laurent N., Esteve J.P., Bedecs K., Buscail L., Vaysse N., Susini C. Sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J. Biol. Chem. 1998, 273:7099-7106.
45. Bousquet C., Puente E., Buscail L., Vaysse N., Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001, 47(Suppl. 2):30-39.
46. Bousquet C., Guillermet-Guibert J., Saint-Laurent N., Archer-Lahlou E., Lopez F., Fanjul M., Ferrand A., Fourmy D., Pichereaux C., Monsarrat B., Pradayrol L., Esteve J.P., Susini C. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J. 2006, 25:3943-3954.
47. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits secretion of immunoreactive pituitary growth hormone. Science 1973, 179:77-79.
48. Bronstein M.D., Sheppard M., Freda P., Gu F., Shen C., Gadelha M., Fleseriu M., Hermosillo-Resendiz K., Ruffin M., Chen Y., Colao A. Pasireotide LAR is significantly more effective than octreotide LAR at providing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. Endocr. Rev. 2012, 33. (abst OR49-3).
49. Brown M., Rivier J., Vale W. Somatostatin-28 selective action on the pancreatic beta-cell and brain. Endocrinology 1981, 108:2391-2393.
50. Bruno J.F., Xu Y., Song J.F., Berelowitz M. Molecular-cloning and functional expression of a brain-specific somatostatin receptor. Proc. Nal. Acad. Sci. U.S.A. 1992, 89:11151-11155.
51. Bruns C., Raulf F., Hoyer D., Schloos J., Lubbert H., Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 1996, 45:17-20.
52. Bruns C., Lewis I., Briner U., Meno-Tetang G., Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 2002, 146:707-716.
53. Brzana J., Yedinak C., Gultekin S., Delashaw J., Fleseriu M. Clinical presentation and response to somatostatin analogue treatment - importance of immunohistochemical granulation pattern and presence of somatostatin receptor subtype 2A in growth hormone secreting adenomas. J. Invest. Med. 2012, 60:178.
54. Buchan A.M.J., Lin C.Y., Choi J., Barber D.L. Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration. J. Biol. Chem. 2002, 277:28431-28438.
55. Buscail L., Delesque N., Esteve J.P., SaintLaurent N., Prats H., Clerc P., Robberecht P., Bell G.I., Liebow C., Schally A.V., Vaysse N., Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogs: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2315-2319.
56. Buscail L., Esteve J.P., SaintLaurent N., Bertrand V., Reisine T., OCarroll A.M., Bell G.I., Schally A.V., Vaysse N., Susini C. Inhibition of cell proliferation by the somatostatin analog RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:1580-1584.
57. Caron P., Beckers A., Cullen D.R., Goth M.I., Gutt B., Laurberg P., Pico A.M., Valimaki M., Zgliczynski W. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metabol. 2002, 87:99-104.
58. Castillo V., Theodoropoulou M., Stalla J., Gallelli M.F., Cabrera-Blatter M.F., Haedo M.R., Labeur M., Schmid H.A., Stalla G.K., Arzt E. Effect of SOM230 (Pasireotide) on corticotropic cells: action in dogs with Cushing's disease. Neuroendocrinology 2011, 94:124-136.
59. Castinetti F., Saveanu A., Morange I., Brue T. Lanreotide for the treatment of acromegaly. Adv. Ther. 2009, 26:600-612.
60. Cattaneo M.G., Amoroso D., Gussoni G., Sanguini A.M., Vicentini L.M. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Lett. 1996, 397:164-168.
61. Cattaneo M.G., Gentilini D., Vicentini L.M. Deregulated human glioma cell motility: inhibitory effect of somatostatin. Mol. Cell. Endocrinol. 2006, 256:34-39.
62. Cazabat L., Bouligand J., Salenave S., Bernier M., Gaillard S., Parker F., Young J., Guiochon-Mantel A., Chanson P. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single center cohort of 443 patients. J. Clin. Endocrinol. Metabol. 2012, 97:E663-E670.
63. Cazabat L., Libe R., Perlemoine K., Rene-Corail F., Burnichon N., Gimenez-Roqueplo A.P., Dupasquier-Fediaevsky L., Bertagna X., Clauser E., Chanson P., Bertherat J., Raffin-Sanson M.L. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 2007, 157:1-8.
64. Cescato R., Waser B., Fani M., Reubi J.C. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J. Nucl. Med. 2011, 52:1886-1890.
65. Cerovac V., Monteserin-Garcia J., Rubinfeld H., Buchfelder M., Losa M., Florio T., Paez-Pereda M., Stalla G.K., Theodoropoulou M. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 2010, 70:666-674.
66. Chahal H.S., Trivellin G., Leontiou C.A., Alband N., Fowkes R.C., Tahir A., Igreja S.C., Chapple J.P., Jordan S., Lupp A., Schulz S., Ansorge O., Karavitaki N., Carlsen E., Wass J.A.H., Grossman A.B., Korbonits M. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metabol. 2012, 97:E1411-E1420.
67. Chan J.A., Ryan D.P., Zhu A.X., Abrams T.A., Wolpin B.M., Malinowski P., Regan E.M., Fuchs C.S., Kulke M.H. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr. Relat. Cancer 2012, 19:615-623.
68. Chanson P., Weintraub B.D., Harris A.G. Octreotide therapy for thyroid stimulating hormone secreting pituitary adenomas: a follow-up of 52 patients. Ann. Intern. Med. 1993, 119:236-240.
69. Cheung N.W., Boyages S.C. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995, 136:4174-4181.
70. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Petroncini M., Liuzzi A., Delpozo E. Medical-treatment of acromegaly with SMS 201-995, a somatostatin analog - a comparison with bromocriptine. J. Clin. Endocrinol. Metabol. 1987, 64:447-453.
71. Colao A., Ferone D., Marzullo P., Cappabianca P., Cirillo S., Boerlin V., Lancranjan I., Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metabol. 2001, 86:2779-2786.
72. Colao A., Petersenn S., Newell-Price J., Findling J.W., Gu F., Maldonado M., Schoenherr U., Mills D., Salgado L.R., Biller B.M.K. A 12-month phase 3 study of pasireotide in Cushing's disease. N. Eng. J. Med. 2012, 366:914-924.
73. Colao A., Pivonello R., Galderisi M., Cappabianca P., Auriemma R.S., Galdiero M., Cavallo L.M., Esposito F., Lombardi G. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J. Clin. Endocrinol. Metabol. 2008, 93:2639-2646.
74. Colao A., Pivonello R., Rosato F., Tita P., Menis E., Barreca A., Ferrara R., Mainini F., Arosio M., Lombardi G. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol. 2006, 64:342-351.
75. Corbetta S., Ballare E., Mantovani G., Lania A., Losa M., Di Blasio A.M., Spada A. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur. J. Clin. Invest. 2001, 31:208-214.
76. Cordelier P., Esteve J.P., Bousquet C., Delesque N., OCarroll A.M., Schally A.V., Vaysse N., Susini C., Buscail L. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:9343-9348.
77. Cordoba-Chacon J., Gahete M.D., Culler M.D., Castano J.P., Kineman R.D., Luque R.M. Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP. J. Neuroendocrinol. 2012, 24:453-463.
78. Cozzi R., Attanasio R., Lodrini S., Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. 2004, 61:209-215.
79. Cozzi R., Attanasio R., Montini M., Pagani G., Lasio G., Lodrini S., Barausse M., Albizzi M., Dallabonzana D., Pedroncelli A.M. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. J. Clin. Endocrinol. Metabol. 2003, 88:3090-3098.
80. Cozzi R., Montini M., Attanasio R., Albizzi M., Lasio G., Lodrini S., Doneda P., Cortesi L., Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metabol. 2006, 91:1397-1403.
81. Cuevas B.D., Lu Y.L., Mao M.L., Zhang J.Y., LaPushin R., Siminovitch K., Mills G.B. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 2001, 276:27455-27461.
82. Culler M.D., Oberg K., Arnold R., Krenning E.P., Sevilla I., Diaz J.A. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metast. Rev. 2011, 30:9-17.
83. Cuny T., Mohamed A., Graillon T., Roche C., Defiles C., Germanetti A.L., Couderc B., Figarella-Branger D., Enjalbert A., Barlier A., Saveanu A. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Mol. Cell. Endocrinol. 2012, 355:106-113.
84. Curtis S.B., Hewitt J., Yakubovitz S., Anzarut A., Hsiang Y.N., Buchan A.M.J. Somatostatin receptor subtype expression and function in human vascular tissue. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1815-H1822.
85. Daly A.F., Tichomirowa M.A., Petrossians P., Heliovaara E., Jaffrain-Rea M.L., Barlier A., Naves L.A., Ebeling T., Karhu A., Raappana A., Cazabat L., De Menis E., Montanana C.F., Raverot G., Weil R.J., Sane T., Maiter D., Neggers S., Yaneva M., Tabarin A., Verrua E., Eloranta E., Murat A., Vierimaa O., Salmela P.I., Emy P., Toledo R.A., Sabate M.I., Villa C., Popelier M., Salvatori R., Jennings J., Longas A.F., Aizpun J.I.L., Georgitsi M., Paschke R., Ronchi C., Valimaki M., Saloranta C., de Herder W., Cozzi R., Guitelman M., Magri F., Lagonigro M.S., Halaby G., Corman V., Hagelstein M.T., Vanbellinghen J.F., Barra G.B., Gimenez-Roqueplo A.P., Cameron F.J., Borson-Chazot F., Holdaway I., Toledo S.P.A., Stalla G.K., Spada A., Zacharieva S., Bertherat J., Brue T., Bours V., Chanson P., Aaltonen L.A., Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metabol. 2010, 95:E373-E383.
86. Davies R.R., Miller M., Turner S.J., Goodship T.H.J., Cook D.B., Watson M., Mcgill A., Orskov H., Alberti K.G.M.M., Johnston D.G. Effects of somatostatin analog SMS 201-995 in normal man. Clin. Endocrinol. 1986, 24:665-674.
87. de Bruin C., Feelders R.A., Waaijers A.M., van Koetsveld P.M., Sprij-Mooij D.M., Lamberts S.W.J., Hofland L.J. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J. Mol. Endocrinol. 2009, 42:47-56.
88. de Bruin C., Pereira A.M., Feelders R.A., Romijn J.A., Roelfsema F., Sprij-Mooij D.M., van Aken M.O., van der Lelij A.J., de W.W., Lamberts S.W.J., Hofland L.J. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metabol. 2009, 94:1118-1124.
89. de Herder W.W., Hofland L.J., van der Lely A.J., Lamberts S.W. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr. Relat. Cancer 2003, 10:451-458.
90. de Herder W.W., Kwekkeboom D.J., Feelders R.A., van Aken M.O., Lamberts S.W., van der Lely A.J., Krenning E.P. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006, 9:243-248.
91. de Jong M., Bakker W.H., Krenning E.P., Breeman W.A., van der Pluijm M.E., Bernard B.F., Visser T.J., Jermann E., Béhé M., Powell P., Mäcke H.R. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 1997, 24:368-371.
92. de Jong M., Breeman W.A., Bakker W.H., Kooij P.P., Bernard B.F., Hofland L.J., Visser T.J., Srinivasan A., Schmidt M.A., Erion J.L., Bugaj J.E., Mäcke H.R., Krenning E.P. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998, 58:437-441.
93. de Jong M., Breeman W.A., Kwekkeboom D.J., Valkema R., Krenning E.P. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res. 2009, 42:873-880.
94. Delesque N., Buscail L., Esteve J.P., Rauly I., Zeggari M., SaintLaurent N., Bell G.I., Schally A.V., Vaysse N., Susini C. A tyrosine phosphatase is associated with the somatostatin receptor. Ciba Found. Symp. 1995, 190:187-196.
95. Demchyshyn L.L., Srikant C.B., Sunahara R.K., Kent G., Seeman P., Vantol H.H.M., Panetta R., Patel Y.C., Niznik H.B. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome-20. Mol. Pharmacol. 1993, 43:894-901.
96. den Bosch J.V., Adriaensen D., Van Nassauw L., Timmermans J.P. The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regul. Pept. 2009, 156:1-8.
97. den Bosch J.V., Torfs P., De Winter B.Y., De Man J.G., Pelckmans P.A., Van Marck E., Grundy D., Van Nassauw L., Timmermans J.P. Effect of genetic SSTR4 ablation on inflammatory peptide and receptor expression in the non-inflamed and inflamed murine intestine. J. Cell. Mol. Med. 2009, 13:3283-3295.
98. Dent P., Reardon D.B., Wood S.L., Lindorfer M.A., Graber S.G., Garrison J.C., Brautigan D.L., Sturgill T.W. Inactivation of Raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by G(alpha i/o) subunits. J. Biol. Chem. 1996, 271:3119-3123.
99. Devane G.W., Siler T.M., Yen S.S.C. Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects. J. Clin. Endocrinol. Metabol. 1974, 38:913-915.
100. Dietrich H., Hu K., Ruffin M., Song D., Bouillaud E., Wang Y., Hasskarl J. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur. J. Endocrinol. 2012, 166:821-828.
101. Douziech N., Calvo E., Coulombe Z., Muradia G., Bastien J., Aubin R.A., Lajas A., Morisset J. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1. Endocrinology 1999, 140:765-777.
102. Drouin J., Delean A., Rainville D., Lachance R., Labrie F. Characteristics of interaction between thyrotropin releasing hormone and somatostatin for thyrotropin and prolactin release. Endocrinology 1976, 98:514-521.
103. Duran-Prado M., Gahete M.D., Hergueta-Redondo M., Martinez-Fuentes A.J., Cordoba-Chacon J., Palacios J., Gracia-Navarro F., Moreno-Bueno G., Malagon M.M., Luque R.M., Castano J.P. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012, 31:2049-2061.
104. Duran-Prado M., Gahete M.D., Martinez-Fuentes A.J., Luque R.M., Quintero A., Webb S.M., Ito-Lopez P., Leal A., Schulz S., Gracia-Navarro F., Malagon M.M., Castano J.P. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J. Clin. Endocrinol. Metabol. 2009, 94:2634-2643.
105. Eriksson B., Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann. Oncol. 1999, 10:S31-S38.
106. Ezzat S., Snyder P.J., Young W.F., Boyajy L.D., Newman C., Klibanski A., Molitch M.E., Boyd A.E., Sheeler L., Cook D.M., Malarkey W.B., Jackson I., Vance M.L., Thorner M.O., Barkan A., Frohman L.A., Melmed S. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann. Intern. Med. 1992, 117:711-718.
107. Faiss S., Rath U., Mansmann U., Caird D., Clemens N., Riecken E.O., Wiedenmann B. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999, 60:469-476.
108. Faiss S., Pape U.F., Böhmig M., Dörffel Y., Mansmann U., Golder W., Riecken E.O., Wiedenmann B. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 2003, 21:2689-2696.
109. Fani M., Del Pozzo L., Abiraj K., Mansi R., Tamma M.L., Cescato R., Waser B., Weber W.A., Reubi J.C., Maecke H.R. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J. Nucl. Med. 2011, 52:1110-1118.
110. Farrall A.J., Ruffin M., Wetli-Hermosillo K., Petersenn S. Long-term treatment of acromegaly with pasireotide (SOM230): results from a phase II extension study. Endocr. Rev. 2010, 31:S856.
111. Fedele M., De Martino I., Pivonello R., Ciarmiello A., de Caro M.L.D., Visone R., Palmieri D., Pierantoni G.M., Arra C., Schmid H.A., Hofland L., Lombardi G., Colao A., Fusco A. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin. Cancer Res. 2007, 13:2738-2744.
112. Feelders R.A., de Bruin C., Pereira A.M., Romijn J.A., Netea-Maier R.T., Hermus A.R., Zelissen P.M., van Heerebeek R., de Jong F.H., van der Lely A.J., de Herder W.W., Hofland L.J., Lamberts S.W. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Eng. J. Med. 2010, 362:1846-1848.
113. Ferjoux G., Lopez F., Esteve J.P., Ferrand A., Vivier E., Vely F., Saint-Laurent N., Pradayrol L., Buscail L., Susini C. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol. Biol. Cell 2003, 14:3911-3928.
114. Ferone D., de Herder W.W., Pivonello R., Kros J.M., van Koetsveld P.M., de Jong T., Minuto F., Colao A., Lamberts S.W.J., Hofland L.J. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J. Clin. Endocrinol. Metabol. 2008, 93:1412-1417.
115. Ferrante E., Pellegrini C., Bondioni S., Peverelli E., Locatelli M., Gelmini P., Luciani P., Peri A., Mantovani G., Bosari S., Beck-Peccoz P., Spada A., Lania A. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer 2006, 13:955-962.
116. Filopanti M., Ronchi C., Ballare E., Bondioni S., Lania A.G., Losa M., Gelmini S., Peri A., Orlando C., Beck-Peccoz P., Spada A. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J. Clin. Endocrinol. Metabol. 2005, 90:4824-4828.
117. Fjallskog M.L., Sundin A., Westlin J.E., Oberg K., Janson E.T., Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med. Oncol. 2002, 19:35-42.
118. Florio T., Arena S., Thellung S., Iuliano R., Corsaro A., Massa A., Pattarozzi A., Bajetto A., Trapasso F., Fusco A., Schettini G. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC CI3 thyroid cell proliferation. Mol. Endocrinol. 2001, 15:1838-1852.
119. Florio T., Barbieri F., Spaziante R., Zona G., Hofland L.J., van Koetsveld P.M., Feelders R.A., Stalla G.K., Theodoropoulou M., Culler M.D., Dong J., Taylor J.E., Moreau J.P., Saveanu A., Gunz G., Dufour H., Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 2008, 15:583-596.
120. Florio T., Morini M., Villa V., Arena S., Corsaro A., Thellung S., Culler M.D., Pfeffer U., Noonan D.M., Schettini G., Albini A. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144:1574-1584.
121. Florio T., Rim C., Hershberger R.E., Loda M., Stork P.J.S. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol. Endocrinol. 1994, 8:1289-1297.
122. Florio T., Schettini G. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J. Mol. Endocrinol. 1996, 17:89-100.
123. Florio T., Scorziello A., Fattore M., Dalto V., Salzano S., Rossi G., Berlingieri M.T., Fusco A., Schettini G. Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine phosphatase activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. J. Biol. Chem. 1996, 271:6129-6136.
124. Florio T., Thellung S., Arena S., Corsaro A., Bajetto A., Schettini G., Stork P.J.S. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J. Physiol. Paris 2000, 94:239-250.
125. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 1999, 141:396-408.
126. Florio T., Yao H., Carey K.D., Dillon T.J., Stork P.J.S. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 1999, 13:24-37.
127. Fougner S.L., Bollerslev J., Latif F., Hald J.K., Lund T., Ramm-Pettersen J., Berg J.P. Low levels of Raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J. Clin. Endocrinol. Metabol. 2008, 93:1211-1216.
128. Fougner S.L., Casar-Borota O., Heck A., Berg J.P., Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 2012, 76:96-102.
129. Fougner S.L., Lekva T., Borota O.C., Hald J.K., Bollerslev J., Berg J.P. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metabol. 2010, 95:2334-2342.
130. Frank M., Klose K.J., Wied M., Ishaque N., Schade-Brittinger C., Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am. J. Gastroenterol. 1999, 94:1381-1387.
131. Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S.H., Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metabol. 2005, 90:4465-4473.
132. Fujii Y., Gonoi T., Yamada Y., Chihara K., Inagaki N., Seino S. Somatostatin receptor subtype Sstr2 mediates the inhibition of high voltage activated calcium channels by somatostatin and its analog SMS-201-995. FEBS Lett. 1994, 355:117-120.
133. Fusco A., Gunz G., Jaquet P., Dufour H., Germanetti A.L., Culler M.D., Barlier A., Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur. J. Endocrinol. 2008, 158:595-603.
134. Fusco A., Lugli F., Sacco E., Tilaro L., Bianchi A., Angelini F., Tofani A., Barini A., Lauriola L., Maira G., Pontecorvi A., De Marinis L. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 2011, 14:351-357.
135. Fusco A., Zatelli M.C., Bianchi A., Cimino V., Tilaro L., Veltri F., Angelini F., Lauriola L., Vellone V., Doglietto F., Ambrosio M.R., Maira G., Giustina A., Uberti E.C.D., Pontecorvi A., De Marinis L. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metabol. 2008, 93:2746-2750.
136. Gasperi M., Petrini L., Pilosu R., Nardi M., Marcello A., Mastio F., Bartalena L., Martino E. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 1993, 16:541-543.
137. Gatta B., Hau D.H., Catargi B., Roger P., Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. 2005, 63:477-478.
138. Gatto F., Barbieri F., Gatti M., Wurth R., Schulz S., Ravetti J.L., Zona G., Culler M.D., Saveanu A., Giusti M., Minuto F., Hofland L.J., Ferone D., Florio T. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin. Endocrinol. 2012, 76:407-414.
139. Gatto F., Feelders R.A., van der Pas R., Kros J.M., Waaijers M., Sprij-Mooij D., Neggers S.J., van der Lelij A.J., Minuto F., Lamberts S.W., de Herder W.W., Ferone D., Hofland L.J. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 2013, 98:E66-E71.
140. Gazal S., Gelerman G., Ziv O., Karpov O., Litman P., Bracha M., Afargan M., Gilon C. Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J. Med. Chem. 2002, 45:1665-1671.
141. Georgitsi M., Raitila A., Karhu A., Tuppurainen K., Makinen M.J., Vierimaa O., Paschke R., Saeger W., van der Luijt R.B., Sane T., Robledo M., De Menis E., Weil R.J., Wasik A., Zielinski G., Lucewicz O., Lubinski J., Launonen V., Vahteristo P., Aaltonen L.A. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4101-4105.
142. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr. Rev. 2006, 27:485-534.
143. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16436-16441.
144. Giustina A., Mazziotti G., Torri V., Spinello M., Floriani I., Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012, 7:e36411.
145. Gomez-Pan A., Reed J.D., Shaw B., Albinus M., Hall R., Besser G.M., Coy D.H., Kastin A.J., Schally A.V. Direct inhibition of gastric acid and pepsin secretion by growth hormone release inhibiting hormone in cats. Lancet 1975, 1:888-890.
146. Gomez-Pan A., Snow M.H., Piercy D.A., Robson V., Wilkinson R., Hall R., Evered D.C., Besser G.M., Schally A.V., Kastin A.J., Coy D.H. Actions of growth hormone release inhibiting hormone (Somatostatin) on renin aldosterone system. J. Clin. Endocrinol. Metabol. 1976, 43:240-243.
147. Gromada J., Hoy M., Buschard K., Salehi A., Rorsman P. Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules. J. Physiol. 2001, 535:519-532.
148. Gruszka A., Culler M.D., Melmed S. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol. Cell. Endocrinol. 2012, 362:104-109.
149. Guillemin R. Somatostatin inhibits release of acetylcholine induced electrically in myenteric plexus. Endocrinology 1976, 99:1653-1654.
150. Guillermet J., Saint-Laurent N., Rochaix P., Cuvillier O., Levade T., Schally A.V., Pradayrol L., Buscail L., Susini C., Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:155-160.
151. Hadcock J.R., Strnad J., Eppler C.M. Rat somatostatin receptor type-1 couples to G-proteins and inhibition of cyclic-AMP accumulation. Mol. Pharmacol. 1994, 45:410-416.
152. Halmos G., Sun B.D., Schally A.V., Hebert F., Nagy A. Human ovarian cancers express somatostatin receptors. J. Clin. Endocrinol. Metabol. 2000, 85:3509-3512.
153. Heisler S., Reisine T.D., Hook V.Y.H., Axelrod J. Somatostatin inhibits multi-receptor stimulation of cyclic-AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:6502-6506.
154. Hejna M., Schmidinger M., Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann. Oncol. 2002, 13:653-668.
155. Helle S.I., Mietlowski W., Guastalla J.P., Szakolczai I., Bajetta E., Sommer H., Baltali E., Pinter T., Csepreghy M., Ottestad L., Boni C., Bryce C., Klijn J.G.M., Lonning P.E. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. Eur. J. Cancer 2005, 41:694-701.
156. Henry R.R., Ciaraldi T.P., Armstrong D., Burke P., Ligueros-Saylan M., Mudaliar S. Hyperglycemia associated with pasireotide:results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013, doi:10.1210/jc.2013-1771.
157. Heron I., Thomas F., Dero M., Gancel A., Ruiz J.M., Schatz B., Kuhn J.M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM-23014 in patients with acromegaly. J. Clin. Endocrinol. Metabol. 1993, 76:721-727.
158. Hershberger R.E., Newman B.L., Florio T., Bunzow J., Civelli O., Li X.J., Forte M., Stork P.J.S. The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in chinese hamster ovary cells via pertussis toxin sensitive pathways. Endocrinology 1994, 134:1277-1285.
159. Hildebrandt J.D., Sekura R.D., Codina J., Iyengar R., Manclark C.R., Birnbaumer L. Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory proteins. Nature 1983, 302:706-709.
160. Hofland L.J., de Herder W.W., Waaijers M., Zuijderwijk J., Uitterlinden P., van Koetsveld P.M., Lamberts S.W.J. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J. Clin. Endocrinol. Metabol. 1999, 84:3336-3343.
161. Hofland L.J., Lamberts S.W.J. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003, 24:28-47.
162. Hofland L.J., Liu Q., van Koetsveld P.M., Zuijderwijk J., van der Ham F., de Krijger R.R., Schonbrunn A., Lamberts S.W.J. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J. Clin. Endocrinol. Metabol. 1999, 84:775-780.
163. Hofland L.J., van der Hoek J., Feelders R., van Aken M.O., van Koetsveld P.M., Waaijers M., Sprij-Mooij D., Bruns C., Weckbecker G., de Herder W.W., Beckers A., Lamberts S.W.J. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 2005, 152:645-654.
164. Hofland L.J., Capello A., Krenning E.P., de Jong M., van Hagen M.P. Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J. Nucl. Med. 2005, 46(Suppl. 1):191S-198S.
165. Hofland L.J., van der Hoek J., van Koetsveld P.M., de Herder W.W., Waaijers M., Sprij-Mooij D., Bruns C., Weckbecker G., Feelders R., van der Lely A.J., Beckers A., Lamberts S.W. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. 2004, 89:1577-1585.
166. Hofmann M., Maecke H., Börner R., Weckesser E., Schöffski P., Oei L., Schumacher J., Henze M., Heppeler A., Meyer J., Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001, 28:751-757.
167. Hortala M., Ferjoux G., Estival A., Bertrand C., Schulz S., Pradayrol L., Susini C., Clemente F. Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform - implication of JAK2. J. Biol. Chem. 2003, 278:20574-20581.
168. Hoyer, D., Epelbaum, J., Feniuk, W., Humphrey, P.P., Meyerhof, W., O'Carroll, A.M., et al., 2000. Somatostatin receptors. In: Watson, S.P., Girdlestone, D. (Eds.), The IUPHAR Compendium of Receptor Characterization and Classification, second ed.
169. Hou C.F., Gilbert R.L., Barber D.L. Subtype specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2. J. Biol. Chem. 1994, 269:10357-10362.
170. Imhof A., Brunner P., Marincek N., Briel M., Schindler C., Rasch H., Mäcke H.R., Rochlitz C., Müller-Brand J., Walter M.A. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 2011, 29:2416-2423.
171. Iuliano R., Trapasso F., Le Pera I., Schepis F., Sama I., Clodomiro A., Dumon K.R., Santoro M., Chiariotti L., Viglietto G., Fusco A. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. 2003, 63:882-886.
172. Jakobs K.H., Aktories K., Schultz G. A nucleotide regulatory site for somatostatin inhibition of adenylate cyclase in S49 lymphoma cells. Nature 1983, 303:177-178.
173. Janson E.T., Stridsberg M., Gobl A., Westlin J.E., Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. 1998, 58:2375-2378.
174. Jaquet P., Gunz G., Saveanu A., Dufour H., Taylor J., Dong J., Kim S., Moreau J.P., Enjalbert A., Culler M.D. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol. 2005, 153:135-141.
175. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metabol. 1999, 84:3268-3276.
176. Johnson M.R., Chowdrey H.S., Thomas F., Grint C., Lightman S.L. Pharmacokinetics and efficacy of the long-acting somatostatin analog somatuline in acromegaly. Eur. J. Endocrinol. 1994, 130:229-234.
177. Kagimoto S., Yamada Y., Kubota A., Someya Y., Ihara Y., Yasuda K., Kozasa T., Imura H., Seino S., Seino Y. Human somatostatin receptor, Sstr2, is coupled to adenylyl cyclase in the presence of Gi alpha 1 protein. Biochem. Biophys. Res. Commun. 1994, 202:1188-1195.
178. Kailey B., van de Bunt M., Cheley S., Johnson P.R., MacDonald P.E., Gloyn A.L., Rorsman P., Braun M. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E1107-E1116.
179. Kaltsas G.A., Papadogias D., Makras P., Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr. Relat. Cancer 2005, 12:683-699.
180. Katznelson L., Oppenheim D.S., Coughlin J.F., Kliman B., Schoenfeld D.A., Klibanski A. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. J. Clin. Endocrinol. Metabol. 1992, 75:1318-1325.
181. Keane M.M., Lowrey G.A., Ettenberg S.A., Dayton M.A., Lipkowitz S. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 1996, 56:4236-4243.
182. Khan S., Krenning E.P., van Essen M., Kam B.L., Teunissen J.J., Kwekkeboom D.J. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [Lu-177-DOTA(0), Tyr(3)]Octreotate. J. Nucl. Med. 2011, 52:1361-1368.
183. Kimura N., Pilichowska M., Date F., Kimura I., Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin. Cancer Res. 1999, 5:3483-3487.
184. Kleuss C., Hescheler J., Ewel C., Rosenthal W., Schultz G., Wittig B. Assignment of G protein subtypes to specific receptors inducing inhibition of calcium currents. Nature 1991, 353:43-48.
185. Klibanski A., Alexander J.M., Bikkal H.A., Hsu D.W., Swearingen B., Zervas N.T. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically non-functioning and somatotroph adenomas in vitro. J. Clin. Endocrinol. Metabol. 1991, 73:1248-1255.
186. Kluxen F.W., Bruns C., Lubbert H. Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4618-4622.
187. Koch B.D., Blalock J.B., Schonbrunn A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J. Biol. Chem. 1988, 263:216-225.
188. Koch B.D., Schonbrunn A. The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. Endocrinology 1984, 114:1784-1790.
189. Koelz A., Kraenzlin M., Gyr K., Meier V., Bloom S.R., Heitz P., Stalder H. Escape of the response to a long-acting somatostatin analog (SMS 201-995) in patients with vipoma. Gastroenterology 1987, 92:527-531.
190. Koerker D.J., Ruch W., Chideckel E., Palmer J., Goodner C.J., Ensinck J., Gale C.C. Somatostatin: hypothalamic inhibitor of endocrine pancreas. Science 1974, 184:482-484.
191. Koerner M., Waser B., Schonbrunn A., Perren A., Reubi J.C. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am. J. Surg. Pathol. 2012, 36:242-252.
192. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S., Nishimoto T., Morgan D.O., Franza B.R., Roberts J.M. Formation and activation of a cyclin E-Cdk2 complex during the G(1)-Phase of the human cell cycle. Science 1992, 257:1689-1694.
193. Konturek S.J., Tasler J., Obtulowicz W., Coy D.H., Schally A.V. Effect of growth hormone release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J. Clin. Invest. 1976, 58:1-6.
194. Koop B.L., Harris A.G., Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur. J. Endocrinol. 1994, 130:581-586.
195. Koumarianou A., Antoniou S., Kanakis G., Economopoulos N., Rontogianni D., Ntavatzikos A., Tsavaris N., Pectasides D., Dimitriadis G., Kaltsas G. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr. Relat. Cancer 2012, 19:L1-L4.
196. Kreienkamp H.J., Akgun E., Baumeister H., Meyerhof W., Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett. 1999, 462:464-466.
197. Kreienkamp H.J., Roth A., Richter D. Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331). DNA Cell Biol. 1998, 17:869-878.
198. Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., Lameris J.S., Reubi J.C., Lamberts S.W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989, 1:242-244.
199. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hagen M., Postema P.T., de Jong M., Reubi J.C., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20:716-731.
200. Kubota A., Yamada Y., Kagimoto S., Seino S., Seino Y. Effector coupling of somatostatin receptor subtypes on human endocrine tumors. Metabolism 1996, 45:42-45.
201. Kubota A., Yamada Y., Kagimoto S., Yasuda K., Someya Y., Ihara Y., Okamoto Y., Kozasa T., Seino S., Seino Y. Multiple effector coupling of somatostatin receptor subtype SSTR1. Biochem. Biophys. Res. Commun. 1994, 204:176-186.
202. Kvols L.K., Moertel C.G., Oconnell M.J., Schutt A.J., Rubin J., Hahn R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analog. N. Eng. J. Med. 1986, 315:663-666.
203. Kvols L.K., Brown M.L., O'Connor M.K., Hung J.C., Hayostek R.J., Reubi J.C., Lamberts S.W. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993, 187:129-133.
204. Kvols L.K., Oberg K.E., O'Dorisio T.M., Mohideen P., de Herder W.W., Arnold R., Hu K., Zhang Y.L., Hughes G., Anthony L., Wiedenmann B. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr. Rel. Cancer 2012, 19:657-666.
205. Kwekkeboom D.J., de Herder W.W., Kam B.L., van Eijck C.H., van Essen M., Kooij P.P., Feelders R.A., van Aken M.O., Krenning E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 2008, 26:2124-2130.
206. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging. Semin. Nucl. Med. 2002, 32:84-91.
207. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., Kooij P.P., de Herder W.W., Feelders R.A., van Eijck C.H., Esser J.P., Kam B.L., Krenning E.P. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005, 23:2754-2762.
208. Kwekkeboom D.J., de Herder W.W., van Eijck C.H., Kam B.L., van Essen M., Teunissen J.J., Krenning E.P. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med. 2010, 40:78-88.
209. Lahlou H., Saint-Laurent N., Esteve J.P., Eychene A., Pradayrol L., Pyronnet S., Susini C. Sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 2003, 278:39356-39371.
210. Lamberts S.W. The role of somatostatin in the regulation of anterior-pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr. Rev. 1988, 9:417-436.
211. Lamberts S.W., Pieters G.F.F.M., Metselaar H.J., Ong G.L., Tan H.S., Reubi J.C. Development of resistance to a long-acting somatostatin analog during treatment of 2 patients with metastatic endocrine pancreatic tumors. Acta Endocrinol. 1988, 119:561-566.
212. Lamberts S.W., Tilanus H.W., Klooswijk A.I.J., Bruining H.A., van der Lely A.J., de Jong F.H. Successful treatment with SMS-201-995 of Cushing syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma. J. Clin. Endocrinol. Metabol. 1988, 67:1080-1083.
213. Lamberts S.W., Uitterlinden P., Klijn J.M. The effect of the long-acting somatostatin analog SMS-201-995 on ACTH secretion in Nelson's syndrome and Cushings disease. Acta Endocrinol. 1989, 120:760-766.
214. Lamberts S.W., Uitterlinden P., Verschoor L., van Dongen K.J., del Pozo E. Long-term treatment of acromegaly with the somatostatin analog SMS 201-995. N. Eng. J. Med. 1985, 313:1576-1578.
215. Lamberts S.W., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1991, 12:450-482.
216. Lamberts S.W., Hofland L.J., de Herder W.W., Kwekkeboom D.J., Reubi J.C., Krenning E.P. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front. Neuroendocrinol. 1993, 14:27-55.
217. Lamberts S.W., van der Lely A.J., deHerder W.W., Hofland L.J. Octreotide. N. Eng. J. Med. 1996, 334:246-254.
218. Lamberts S.W., Zweens M., Verschoor L., del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J. Clin. Endocrinol. Metabol. 1986, 63:16-19.
219. Lamers C.B. Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract. Acta. Endocrinol. Suppl. (Copenh) 1987, 286:19-25.
220. Law S.F., Yasuda K., Bell G.I., Reisine T. Gi alpha-3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. J. Biol. Chem. 1993, 268:10721-10727.
221. Lee M.T., Liebow C., Kamer A.R., Schally A.V. Effects of epidermal growth-factor and analogs of luteinizing-hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1656-1660.
222. Leontiou C.A., Gueorguiev M., van der Spuy J., Quinton R., Lolli F., Hassan S., Chahal H.S., Igreja S.C., Jordan S., Rowe J., Stolbrink M., Christian H.C., Wray J., Bishop-Bailey D., Berney D.M., Wass J.A.H., Popovic V., Ribeiro-Oliveira A., Gadelha M.R., Monson J.P., Akker S.A., Davis J.R.E., Clayton R.N., Yoshimoto K., Iwata T., Matsuno A., Eguchi K., Musat M., Flanagan D., Peters G., Bolger G.B., Chapple J.P., Frohman L.A., Grossman A.B., Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metabol. 2008, 93:2390-2401.
223. Lesche S., Lehmann D., Nagel F., Schmid H.A., Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metabol. 2009, 94:654-661.
224. Leyton J., Iddon L., Perumal M., Indrevoll B., Glaser M., Robins E., George A.J., Cuthbertson A., Luthra S.K., Aboagye E.O. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET. J. Nucl. Med. 2011, 52:1441-1448.
225. Levy A., Lightman S.L. Quantitative in-situ hybridization histochemistry studies on growth hormone (GH) gene expression in acromegalic somatotrophs: effects of somatostatin, GH-releasing factor and cortisol. J. Mol. Endocrinol. 1988, 1:19-26.
226. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
227. Lin C.Y., Varma M.G., Joubel A., Madabushi S., Lichtarge O., Barber D.L. Conserved motifs in somatostatin, D-2-dopamine, and alpha(2B)-adrenergic receptors for inhibiting the Na-H exchanger, NHE1. J. Biol. Chem. 2003, 278:15128-15135.
228. + exchanger isoforms. J. Biol. Chem. 1996, 271:22604-22610.
229. Liu D., Martino G., Thangaraju M., Sharma M., Halwani F., Shen S.H., Patel Y.C., Srikant C.B. Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis. J. Biol. Chem. 2000, 275:9244-9250.
230. Lombardi G., Minuto F., Tamburrano G., Ambrosio M.R., Arnaldi G., Arosio M., Chiarini V., Cozzi R., Grottoli S., Mantero F., Bogazzi F., Terzolo M., Tita P., Boscani P.F., Colao A. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J. Endocrinol. Invest. 2009, 32:202-209.
231. Lopez F., Esteve J.P., Buscail L., Delesque N., Saint Laurent N., Theveniau M., Nahmias C., Vaysse N., Susini C. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J. Biol. Chem. 1997, 272:24448-24454.
232. Lopez F., Esteve J.P., Buscail L., Delesque N., SaintLaurent N., Vaysse N., Susini C. Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Metabolism 1996, 45:14-16.
233. Lopez F., Ferjoux G., Cordelier P., Saint-Laurent N., Esteve J.P., Vaysse N., Buscail L., Susini C. Neuronal nitric oxide synthase is a SHP-1 substrate involved in sst2 somatostatin receptor growth inhibitory signaling. FASEB J. 2001, 15:2300-2302.
234. Luque R.M., Duran-Prado M., Garcia-Navarro S., Gracia-Navarro F., Kineman R.D., Malagon M.M., Castano J.P. Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion. Endocrinology 2006, 147:2902-2908.
235. 2+ influx. Endocrinology 1991, 128:583-591.
236. Luttrell L.M., Lefkowitz R.J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 2002, 115:455-465.
237. Ma P., Wang Y., van der Hoek J., Nedelman J., Schran H., Tran L.L., Lamberts S.W. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin. Pharmacol. Ther. 2005, 78:69-80.
238. Maison P., Tropeano A.I., Macquin-Mavier I., Giustina A., Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metabol. 2007, 92:1743-1747.
239. Massa A., Barbieri F., Aiello C., Arena S., Pattarozzi A., Pirani P., Corsaro A., Iuliano R., Fusco A., Zona G., Spaziante R., Florio T., Schettini G. The expression of the phosphotyrosine phosphatase DEP-1/PTP eta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. J. Biol. Chem. 2004, 279:29004-29012.
240. Mattar P., Martins M.R.A., Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinology 2010, 92:120-127.
241. Mazziotti G., Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010, 13:60-67.
242. Meisetschläger G., Poethko T., Stahl A., Wolf I., Scheidhauer K., Schottelius M., Herz M., Wester H.J., Schwaiger M. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J. Nucl. Med. 2006, 47:566-573.
243. Melmed S. Medical progress: acromegaly. N. Eng. J. Med. 2006, 355:2558-2573.
244. Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M.L., Ho K., Giustina A. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metabol. 2009, 94:1509-1517.
245. Melmed S., Sternberg R., Cook D., Klibanski A., Chanson P., Bonert V., Vance M.L., Rhew D., Kleinberg D., Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metabol. 2005, 90:4405-4410.
246. Mercado M., Borges F., Bouterfa H., Chang T.C., Chervin A., Farrall A.J., Patocs A., Petersenn S., Podoba J., Safari M., Wardlaw J. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. 2007, 66:859-868.
247. 2+ current modulated by cGMP-dependent protein kinase. Nature 1994, 369:336-339.
248. Merola B., Cittadini A., Colao A., Ferone D., Fazio S., Sabatini D., Biondi B., Sacca L., Lombardi G. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J. Clin. Endocrinol. Metabol. 1993, 77:790-793.
249. Meyerhof W., Wulfsen I., Schonrock C., Fehr S., Richter D. Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10267-10271.
250. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
251. Montini M., Gianola D., Pagani M.D., Pedroncelli A., Caldara R., Gherardi F., Bonelli M., Lancranjan I., Pagani G. Cholelithiasis and acromegaly: therapeutic strategies. Clin. Endocrinol. 1994, 40:401-406.
252. Morishita M., Iwasaki Y., Onishi A., Asai M., Mutsuga N., Yoshida M., Oiso Y., Inoue K., Murohara T. The effects of GH-releasing hormone/somatostatin on the 5'-promoter activity of the GH gene in vitro. J. Mol. Endocrinol. 2003, 31:441-448.
253. Moss C.E., Marsh W.J., Parker H.E., Ogunnowo-Bada E., Riches C.H., Habib A.M., Evans M.L., Gribble F.M., Reimann F. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 2012, 55:3094-3103.
254. Murray R.D., Kim K., Ren S.G., Chelly M., Umehara Y., Melmed S. Central and peripheral actions of somatostatin on the growth hormone - IGF-I axis. J. Clin. Invest. 2004, 114:349-356.
255. Murray R.D., Kim K., Ren S.G., Lewis I., Weckbecker G., Bruns C., Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J. Clin. Endocrinol. Metabol. 2004, 89:3027-3032.
256. Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metabol. 2008, 93:2957-2968.
257. Najib S., Saint-Laurent N., Esteve J.P., Schulz S., Boutet-Robinet E., Fourmy D., Lattig J., Mollereau C., Pyronnet S., Susini C., Bousquet C. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin a negatively controls the PI3K pathway. Mol. Cell. Biol. 2012, 32:1004-1016.
258. Namba H., Morita S., Melmed S. Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic-acid levels: interaction with somatostatin. Endocrinology 1989, 124:1794-1799.
259. Neggers S.J., de Herder W.W., Janssen J.A., Feelders R.A., van der Lely A.J. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 2009, 160:529-533.
260. Newman C.B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molitch M.E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M.L., Barkan A., Frohman L., Kleinberg D.L. Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metabol. 1998, 83:3034-3040.
261. Newman C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M.E., Gagel R.F., Boyd A.E., Sheeler L., Cook D., Malarkey W.B., Jackson I.M.D., Vance M.L., Thorner M.O., Ho P.J., Jaffe C.A., Frohman L.A., Kleinberg D.L. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J. Clin. Endocrinol. Metabol. 1995, 80:2768-2775.
262. Nicholl C.G., Polak J.M., Bloom S.R. The hormonal regulation of food intake, digestion, and absorption. Ann. Rev. Nutr. 1985, 5:213-239.
263. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
264. Obari A., Sano T., Ohyama K., Kudo E., Qian Z.R., Yoneda A., Rayhan N., Rahman M.M., Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 2008, 19:82-91.
265. Oberg K. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Expert Rev. Anticancer Ther. 2009, 9:557-566.
266. Oberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?. Endocrine 2012, 42:3-4.
267. Oberg K.E., Reubi J.C., Kwekkeboom D.J., Krenning E.P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139:742-753.
268. O'Carroll A.M., Lolait S.J., Konig M., Mahan L.C. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol. Pharmacol. 1992, 42:939-946.
269. O'Carroll A.M., Raynor K., Lolait S.J., Reisine T. Characterization of cloned human somatostatin receptor SSTR5. Mol. Pharmacol. 1994, 46:291-298.
270. Ono K., Suzuki T., Miki Y., Taniyama Y., Nakamura Y., Noda Y., Watanabe M., Sasano H. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007, 27:2231-2239.
271. Onofri C., Theodoropoulou M., Losa M., Uhl E., Lange M., Arzt E., Stalla G.K., Renner U. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J. Endocrinol. 2006, 191:249-261.
272. Oriola J., Lucas T., Halperin I., Mora M., Perales M.J., varez-Escola C., Paz D., Soto G.D., Salinas I., Julian M.T., Olaizola I., Bernabeu I., Marazuela M., Puig-Domingo M. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur. J. Endocrinol. 2013, 168:9-13.
273. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998, 351:417-418.
274. Pace C.S., Tarvin J.T. Somatostatin: mechanism of action in pancreatic-islet beta-cells. Diabetes 1981, 30:836-842.
275. Pages P., Benali N., Saint-Laurent N., Esteve J.P., Schally A.V., Tkaczuk J., Vaysse N., Susini C., Buscail L. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1) - evidence for the role of SHP-1. J. Biol. Chem. 1999, 274:15186-15193.
276. Pagotto U., Arzberger T., Ciani E., Lezoualc'h F., Pilon C., Journot L., Spengler D., Stalla G.K. Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology 1999, 140:987-996.
277. Pagotto U., Arzberger T., Theodoropoulou M., Grubler Y., Pantaloni C., Saeger W., Losa M., Journot L., Stalla G.K., Spengler D. The expression of the antiproliferative gene ZAC is lost or highly reduced in non-functioning pituitary adenomas. Cancer Res. 2000, 60:6794-6799.
278. Pan M.G., Florio T., Stork P.J.S. G-protein activation of a hormone-stimulated phosphatase in human tumor-cells. Science 1992, 256:1215-1217.
279. Papotti M., Kumar U., Volante M., Pecchioni C., Patel Y.C. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin. Endocrinol. 2001, 54:641-649.
280. Park C.Y., Yang I.Y., Woo J.T., Kim S.W., Kim J.W., Kim Y.S., Sohn S.J., Kim E.H., Lee M., Park H.S., Jung J.C., Park S.J. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr. J. 2004, 51:227-236.
281. Parmar H., Bogden A., Mollard M., Derouge B., Phillips R.H., Lightman S.L. Somatostatin and somatostatin analogs in oncology. Cancer Treat. Rev. 1989, 16:95-115.
282. Pasquali D., Rossi V., Conzo G., Pannone G., Bufo P., De Bellis A., Renzullo A., Bellastella G., Colao A., Vallone G., Bellastella A., Sinisi A.A. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J. Mol. Endocrinol. 2008, 40:263-271.
283. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20:157-198.
284. Patel Y.C., Greenwood M., Kent G., Panetta R., Srikant C.B. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem. Biophys. Res. Commun. 1993, 192:288-294.
285. Patel Y.C., Greenwood M.T., Warszynska A., Panetta R., Srikant C.B. All 5 cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl-cyclase. Biochem. Biophys. Res. Commun. 1994, 198:605-612.
286. Patel Y.C., Wheatley T. In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat. Endocrinology 1983, 112:220-225.
287. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Cutsem E., Yao J.C. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
288. Petersenn S., Heyens M., Ludecke D.K., Beil F.U., Schulte H.M. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clin. Endocrinol. 2000, 52:35-42.
289. Petersenn S., Schopohl J., Barkan A., Mohideen P., Colao A., Abs R., Buchelt A., Ho Y.Y., Hu K., Farrall A.J., Melmed S., Biller B.M.K. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metabol. 2010, 95:2781-2789.
290. Peverelli E., Lania A.G., Mantovani G., Beck-Peccoz P., Spada A. Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop. Endocrinology 2009, 150:3169-3176.
291. Peverelli E., Olgiati L., Locatelli M., Magni P., Fustini M.F., Frank G., Mantovani G., Beck-Peccoz P., Spada A., Lania A. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett. 2010, 288:170-176.
292. Pivonello R., Ferone D., de Herder W.W., de Krijger R.R., Waaijers M., Mooij D.M., van Koetsveld P.M., Barreca A., de Caro M.L.D., Lombardi G., Colao A., Lamberts S.W.J., Hofland L.J. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J. Clin. Endocrinol. Metabol. 2004, 89:4493-4502.
293. Pivonello R., Ferone D., de Herder W.W., Kros J.M., de Caro M.L.D., Arvigo M., Annunziato L., Lombardi G., Colao A., Hofland L.J., Lamberts S.W. Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metabol. 2004, 89:2452-2462.
294. Plewe G., Krause U., Beyer J., Neufeld M., Delpozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analog SMS-201-995 in acromegaly. Lancet 1984, 2:782-784.
295. Plockinger U., Albrecht S., Mawrin C., Saeger W., Buchfelder M., Petersenn S., Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J. Clin. Endocrinol. Metabol. 2008, 93:1203-1210.
296. Plockinger U., Dienemann D., Quabbe H.J. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J. Clin. Endocrinol. Metabol. 1990, 71:1658-1662.
297. Plockinger U., Hoffmann U., Geese M., Lupp A., Buchfelder M., Flitsch J., Vajkoczy P., Jakob W., Saeger W., Schulz S., Dohrmann C. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4-and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in octreotide non-responsive tumours. Eur. J. Endocrinol. 2012, 166:223-234.
298. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone secreting and clinically non-functioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metabol. 1994, 79:1416-1423.
299. Pola S., Cattaneo M.G., Vicentini L.M. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells - involvement of Rac and MAP kinase activity. J. Biol. Chem. 2003, 278:40601-40606.
300. Pritchard K.I., Shepherd L.E., Chapman J.A.W., Norris B.D., Cantin J., Goss P.E., Dent S.F., Walde D., Vandenberg T.A., Findlay B., O'Reilly S.E., Wilson C.F., Han L., Piura E., Whelan T.J., Pollak M.N. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J. Clin. Oncol. 2011, 29:3869-3876.
301. Qian X., Jin L., Grande J.P., Lloyd R.V. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996, 137:3051-3060.
302. Qiu C., Zeyda T., Johnson B., Hochgeschwender U., de Lecea L., Tallent M.K. Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. J. Neurosci. 2008, 28:3567-3576.
303. Quinn T.J., Yuan Z.Q., Adem A., Geha R., Vrikshajanani C., Koba W., Fine E., Hughes D.T., Schmid H.A., Libutti S.K. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery 2012, 152:1068-1076.
304. Raptis S., Berger L.V., Schlegel W., Schroder K.E., Pfeiffer E.F., Dollinger H.C. Effects of somatostatin on gastric secretion and gastrin release in man. Digestion 1975, 13:15-26.
305. Reardon D.B., Dent P., Wood S.L., Kong T., Sturgill T.W. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol. Endocrinol. 1997, 11:1062-1069.
306. Reardon D.B., Wood S.L., Brautigan D.L., Bell G.I., Dent P., Sturgill T.W. Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochem. J. 1996, 314:401-404.
307. Redfern J.S., Fortuner W.J. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am. J. Gastroenterol. 1995, 90:1042-1052.
308. Reisine T., Axelrod J. Prolonged somatostatin pretreatment desensitizes somatostatins inhibition of receptor mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase. Endocrinology 1983, 113:811-813.
309. Ren S.G., Kim S., Taylor J., Dong J.S., Moreau J.P., Culler M.D., Melmed S. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metabol. 2003, 88:5414-5421.
310. Renner U., Arzberger T., Pagotto U., Leimgruber S., Uhl E., Muller A., Lange M., Weindl A., Stalla G.K. Heterogenous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically non-functioning pituitary adenomas. J. Clin. Endocrinol. Metabol. 1998, 83:1368-1375.
311. Renstrom E., Ding W.G., Bokvist K., Rorsman P. Neurotransmitter induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin. Neuron 1996, 17:513-522.
312. Reubi J.C., Kappeler A., Waser B., Laissue J., Hipkin R.W., Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am. J. Pathol. 1998, 153:233-245.
313. Reubi J.C., Krenning E., Lamberts S.W.J., Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism 1992, 41:104-110.
314. Reubi J.C., Kvols L.K., Waser B., Nagorney D.M., Heitz P.U., Charboneau J.W., Reading C.C., Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle-biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990, 50:5969-5977.
315. Reubi J.C., Laissue J., Krenning E., Lamberts S.W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 1992, 43:27-35.
316. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001, 28:836-846.
317. Reubi J.C., Waser B., Schaer J.C., Markwalder R. Somatostatin receptors in human prostate and prostate-cancer. J. Clin. Endocrinol. Metabol. 1995, 80:2806-2814.
318. Ricci G.L., Fevery J. Cholestatic action of somatostatin in the rat - effect on the different fractions of bile secretion. Gastroenterology 1981, 81:552-562.
319. Richardson U.I., Schonbrunn A. Inhibition of adrenocorticotropin secretion by somatostatin in pituitary-cells in culture. Endocrinology 1981, 108:281-290.
320. Rinke A., Muller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T., Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 2009, 27:4656-4663.
321. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288:154-157.
322. Rocheville M., Lange D.C., Kumar U., Sasi R., Patel R.C., Patel Y.C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 2000, 275:7862-7869.
323. Rohrer L., Raulf F., Bruns C., Buettner R., Hofstaedter F., Schule R. Cloning and characterization of a 4th human somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:4196-4200.
324. Roosterman D., Kreuzer O.J., Brune N., Cottrell G.S., Bunnett N.W., Meyerhof W., Steinhoff M. Agonist-induced endocytosis of rat somatostatin receptor 1. Endocrinology 2007, 148:1050-1058.
325. Rosenthal J., Escobarjimenez F., Raptis S. Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-receptor stimulation. Clin. Endocrinol. 1977, 6:455-462.
326. Rossowski W.J., Gu Z.F., Akarca U.S., Jensen R.T., Coy D.H. Characterization of somatostatin receptor subtypes controlling rat gastric-acid and pancreatic amylase release. Peptides 1994, 15:1421-1424.
327. Ruan W.F., Fahlbusch F., Clemmons D.R., Monaco M.E., Walden P.D., Silva A.P., Schmid H.A., Kleinberg D.L. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?. Mol. Endocrinol. 2006, 20:426-436.
328. Ruszniewski P., Ducreux M., Chayvialle J.A., Blumberg J., Cloarec D., Michel H., Raymond J.M., Dupas J.L., Gouerou H., Jian R., Genestin E., Bernades P., Rougier P. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996, 39:279-283.
329. Sakanaka C., Ferby I., Waga I., Bito H., Shimizu T. On the mechanism of cytosolic phospholipase A2 Activation in CHO cells carrying somatostatin receptor: wortmannin-sensitive pathway to activate mitogen-activated protein kinase. Biochem. Biophys. Res. Commun. 1994, 205:18-23.
330. Saveanu A., Gunz G., Guillen S., Dufour H., Culler M.D., Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006, 83:258-263.
331. Saveanu A., Lavaque E., Gunz G., Barlier A., Kim S., Taylor J.E., Culler M.D., Enjalbert A., Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metabol. 2002, 87:5545-5552.
332. Schally A.V. Oncological applications of somatostatin analogs. Cancer Res. 1988, 48:6977-6985.
333. Schally A.V., Huang W.Y., Chang R.C.C., Arimura A., Redding T.W., Millar R.P., Hunkapiller M.W., Hood L.E. Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. Proc. Natl. Acad. Sci. U.S.A. 1980, 77:4489-4493.
334. Schettini G. Brain Somatostatin: receptor-coupled transducing mechanisms and role in cognitive functions. Pharmacol. Res. 1991, 23:203-215.
335. Schlegel W., Wuarin F., Zbaren C., Wollheim C.B., Zahnd G.R. Pertussis toxin selectively abolishes hormone induced lowering of cytosolic calcium in Gh3 cells. FEBS Lett. 1985, 189:27-32.
336. Schmid H.A., Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80:47-50.
337. Schmid H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol. Cell. Endocrinol. 2008, 286:69-74.
338. Schmid H.A., Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J. Endocrinol. 2012, 212:49-60.
339. Schottelius M., Poethko T., Herz M., Reubi J.C., Kessler H., Schwaiger M., Wester H.J. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin. Cancer Res. 2004, 10:3593-3606.
340. Schulz S., Schulz S., Schmitt J., Wiborny D., Schmidt H., Olbricht S., Weise W., Roessner A., Gramsch C., Hollt V. Immunocytochemical detection of somatostatin receptors sst(1), sst(2A), sst(2B), and sst(3) in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin. Cancer Res. 1998, 4:2047-2052.
341. Schwarz J.K., Devoto S.H., Smith E.J., Chellappan S.P., Jakoi L., Nevins J.R. Interactions of the P107 and Rb proteins with E2F during the cell proliferation response. EMBO J. 1993, 12:1013-1020.
342. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 1995, 9:726-735.
343. Sellers L.A. Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of G(i/o)-coupled somatostatin sst(4) receptors. J. Biol. Chem. 1999, 274:24280-24288.
344. Sellers L.A., Alderton F., Carruthers A.M., Schindler M., Humphrey P.P. Receptor isoforms mediate opposing proliferative effects through gbetagamma-activated p38 or Akt pathways. Mol. Cell. Biol. 2000, 20:5974-5985.
345. Sellers L.A., Feniuk W., Humphrey P.P., Lauder H. Activated g protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation. J. Biol. Chem. 1999, 274:16423-16430.
346. Selvarajah D., Webster J., Ross R., Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 2005, 152:569-574.
347. Sharma K., Patel Y.C., Srikant C.B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 1996, 10:1688-1696.
348. Sharma K., Srikant C.B. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int. J. Cancer 1998, 76:259-266.
349. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
350. Shenouda, M., Maldonado, M., Wang, Y., Bouillaud, E., Hudson, M., Nesheiwat, D., Hu, K., 2012. An open-label, dose-escalation study of once- and twice-daily pasireotide in healthy volunteers: safety, tolerability and effects on glucose, insulin and glucagon levels. Am. J. Ther. June 16 (Epub ahead of print).
351. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60:3689-3695.
352. Shimon I., Rubinek T., Hadani M., Alhadef N. PTR-3173 (Somatoprim (TM)), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J. Endocrinol. Invest. 2004, 27:721-727.
353. Shimon I., Taylor J.E., Dong J.Z., Bitonte R.A., Kim S., Morgan B., Coy D.H., Culler M.D., Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures - differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin. Invest. 1997, 99:789-798.
354. Shimon I., Yan X.M., Taylor J.E., Weiss M.H., Culler M.D., Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas - novel potential therapy for functional pituitary tumors. J Clin. Invest. 1997, 100:2386-2392.
355. Siler T.M., Yen S.C., Vale W., Guillemin R. Inhibition by somatostatin on release of TSH induced in man by thyrotropin-releasing factor. J. Clin. Endocrinol. Metabol. 1974, 38:742-745.
356. Simard J., Labrie F., Gossard F. Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. DNA 1986, 5:263-270.
357. + conductance in freshly dispersed rat somatotrophs. J. Physiol. 1991, 441:615-637.
358. Singh V., Brendel M.D., Zacharias S., Mergler S., Jahr H., Wiedenmann B., Bretzel R.G., Plockinger U., Strowski M.Z. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J. Clin. Endocrinol. Metabol. 2007, 92:673-680.
359. Smalley K.S.M., Feniuk W., Sellers L.A., Humphrey P.P.A. The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification. Biochem. Biophys. Res. Commun. 1999, 263:239-243.
360. 2+-channels in murine pancreatic beta-cells are inhibited by an exclusive coupling with somatostatin receptor subtype 1. Endocrinology 2009, 150:741-748.
361. Spada A., Arosio M., Bochicchio D., Bazzoni N., Vallar L., Bassetti M., Faglia G. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary-tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metabol. 1990, 71:1421-1426.
362. Spengler D., Villalba M., Hoffmann A., Pantaloni C., Houssami S., Bockaert J., Journot L. Regulation of apopotosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J. 1997, 16:2814-2825.
363. Srikant C.B. Cell cycle dependent induction of apoptosis by somatostatin analog SMS-201-995 in AtT-20 mouse pituitary cells. Biochem. Biophys. Res. Commun. 1995, 209:400-406.
364. Srikant C.B., Shen S.H. Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996, 137:3461-3468.
365. Stalla G.K., Brockmeier S.J., Renner U., Newton C., Buchfelder M., Stalla J., Muller O.A. Octreotide exerts different effects in-vivo and in-vitro in Cushings-disease. Eur. J. Endocrinol. 1994, 130:125-131.
366. Steffin B., Gutt B., Bidlingmaier M., Dieterle C., Oltmann F., Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol. 2006, 155:73-78.
367. Stetak A., Csermely P., Ullrich A., Keri G. Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKC delta. Biochem. Biophys. Res. Commun. 2001, 288:564-572.
368. Strowski M.Z., Dashkevicz M.P., Parmar R.M., Wilkinson H., Kohler M., Schaeffer J.M., Blake A.D. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002, 75:339-346.
369. Strowski M.Z., Kohler M., Chen H.Y., Trumbauer M.E., Li Z.H., Szalkowski D., Gopal-Truter S., Fisher J.K., Schaeffer J.M., Blake A.D., Zhang B.B., Wilkinson H.A. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. 2003, 17:93-106.
370. Strowski M.Z., Parmar R.M., Blake A.D., Schaeffer J.M. Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000, 141:111-117.
371. Sugihara H., Minami S., Okada K., Kamegai J., Hasegawa O., Wakabayashi I. Somatostatin reduces transcription of the growth-hormone gene in rats. Endocrinology 1993, 132:1225-1229.
372. Taboada G.F., Luque R.M., Vieira L., Machado E.D., Sbaffi B.C., Domingues R.C., Marcondes J.B., Chimelli L.M.C., Fontes R., Niemeyer P., de Carvalho D.P., Kineman R.D., Gadelha M.R. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol. 2008, 158:295-303.
373. Taboada G.F., Neto L.V., Luque R.M., Cordoba-Chacon J., Machado E.D., de Carvalho D.P., Kineman R.D., Gadelha M.R. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas. Neuroendocrinology 2011, 93:40-47.
374. 2+ current in the pituitary cell line AtT-20. Neuroscience 1996, 71:1073-1081.
375. Tanner J.W., Davis S.K., Mcarthur N.H., French J.T., Welsh T.H. Modulation of growth-hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophyseal cells. J. Endocrinol. 1990, 125:109-115.
376. Taylor J.E., Bogden A.E., Moreau J.P., Coy D.H. In vitro and in vivo inhibition of human small cell lung-carcinoma (NCI-H69) growth by a somatostatin analog. Biochem. Biophys. Res. Commun. 1988, 153:81-86.
377. Teichman S.L., Tuvia S., Atsmon J., Katz S., Salama P., Pelled D., Landau I., Karmeli I., Kramer W.G., Strasburger C.J., Bidlingmaier M., Kleinberg D.L., Melmed S., Mamluk R. Octreolin™ pharmacodynamics: an oral octreotide formulation to treat acromegaly suppresses growth hormone in healthy volunteers. Endocr. Rev. 2012, 33. (OR49-4).
378. Teijeiro R., Rios R., Costoya J.A., Castro R., Bello J.L., Devesa J., Arce V.M. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell. Physiol. Biochem. 2002, 12:31-38.
379. Tentler J.J., Hadcock J.R., Gutierrez-Hartmann A. Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol. Endocrinol. 1997, 11:859-866.
380. Teunissen J.J., Kwekkeboom D.J., Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J. Clin. Oncol. 2004, 22:2724-2729.
381. Thangaraju M., Sharma K., Leber B., Andrews D.W., Shen S.H., Srikant C.B. Regulation of acidification and apoptosis by SHP-1 and Bcl-2. J. Biol. Chem. 1999, 274:29549-29557.
382. Theodoropoulou M., Stalla G.K., Spengler D. ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 2010, 326:60-65.
383. Theodoropoulou M., Tichomirowa M.A., Sievers C., Yassouridis A., Arzberger T., Hougrand O., Deprez M., Daiy A.F., Petrossians P., Pagotto U., Beckers A., Stalla G.K. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int. J. Cancer 2009, 125:2122-2126.
384. Theodoropoulou M., Zhang J., Laupheimer S., Paez-Pereda M., Erneux C., Florio T., Pagotto U., Stalla G.K. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006, 66:1576-1582.
385. Tichomirowa M.A., Barlier A., Daly A.F., Jaffrain-Rea M.L., Ronchi C., Yaneva M., Urban J.D., Petrossians P., Elenkova A., Tabarin A., Desailloud R., Maiter D., Schurmeyer T., Cozzi R., Theodoropoulou M., Sievers C., Bernabeu I., Naves L.A., Chabre O., Montanana C.F., Hana V., Halaby G., Delemer B., Aizpun J.I.L., Sonnet E., Longas A.F., Hagelstein M.T., Caron P., Stalla G.K., Bours V., Zacharieva S., Spada A., Brue T., Beckers A. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur. J. Endocrinol. 2011, 165:509-515.
386. Toledo R.A., Lourenco D.M., Liberman B., Cunha-Neto M.B.C., Cavalcanti M.G., Moyses C.B., Toledo S.P.A., Dahia P.L.M. Germline mutation in the Aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metabol. 2007, 92:1934-1937.
387. 2+ mobilization. Biochem. Biophys. Res. Commun. 1994, 200:986-992.
388. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., Dimaraki E.V., Stewart P.M., Friend K.E., Vance M.L., Besser G.M., Scarlett J.A., Thorner M.O., Parkinson C., Klibanski A., Powell J.S., Barkan A.L., Sheppard M.C., Maldonado M., Rose D.R., Clemmons D.R., Johannson G., Bengtsson B.A., Stavrou S., Kleinberg D.L., Cook D.M., Phillips L.S., Bidlingmaier M., Strasburger C.J., Hackett S., Zib K., Bennett W.F., Davis R.J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Eng. J. Med. 2000, 342:1171-1177.
389. Tsukamoto N., Nagaya T., Kuwayama A., Takano K., Shizume K., Sugita K., Seo H. Octreotide treatment results in the inhibition of GH gene-expression in the adenoma of the patients with acromegaly. Endocrine J. 1994, 41:437-444.
390. Tsuzaki S., Moses A.C. Somatostatin inhibits deoxyribonucleic-acid synthesis induced by both thyrotropin and insulin-like growth factor-i in FRTL5 cells. Endocrinology 1990, 126:3131-3138.
391. Tulipano G., Stumm R., Pfeiffer M., Kreienkamp H.J., Hollt V., Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 2004, 279:21374-21382.
392. Tyrrell J.B., Lorenzi M., Gerich J.E., Forsham P.H. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. J. Clin. Endocrinol. Metabol. 1975, 40:1125-1127.
393. Vale W., Rivier C., Brazeau P., Guillemin R. Effects of somatostatin on secretion of thyrotropin and prolactin. Endocrinology 1974, 95:968-977.
394. Valkema R., Pauwels S., Kvols L.K., Barone R., Jamar F., Bakker W.H., Kwekkeboom D.J., Bouterfa H., Krenning E.P. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med. 2006, 36:147-156.
395. Vallabhajosula S., Moyer B.R., Lister-James J., McBride B.J., Lipszyc H., Lee H., Bastidas D., Dean R.T. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J. Nucl. Med. 1996, 37:1016-1022.
396. van Der Hoek J., de Herder W.W., Feelders R.A., van der Lely A.J., Uitterlinden P., Boerlin V., Bruns C., Poon K.W., Lewis I., Weckbecker G., Krahnke T., Hofland L.J., Lamberts S.W. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. 2004, 89:638-645.
397. van Der Hoek J., Waaijers M., van Koetsveld P.M., Sprij-Mooij D., Feelders R.A., Schmid H.A., Schoeffter P., Hoyer D., Cervia D., Taylor J.E., Culler M.D., Lamberts S.W., Hofland L.J. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E278-E287.
398. van der Lely A.J., Hutson R.K., Trainer P.J., Besser G.M., Barkan A.L., Katznelson L., Klibanski A., Herman-Bonert V., Melmed S., Vance M.L., Freda P.U., Stewart P.M., Friend K.E., Clemmons D.R., Johannsson G., Stavrou S., Cook D.M., Phillips L.S., Strasburger C.J., Hacker S., Zib K.A., Davis R.J., Scarlett J.A., Thorner M. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
399. Vanetti M., Kouba M., Wang X.M., Vogt G., Hollt V. Cloning and expression of a novel mouse somatostatin receptor (Sstr2B). FEBS Lett. 1992, 311:290-294.
400. van Hagen P.M., Krenning E.P., Kwekkeboom D.J., Reubi J.C., Anker-Lugtenburg P.J., Lowenberg B., Lamberts S.W. Somatostatin and the immune and hematopoietic system: a review. Eur. J. Clin. Invest. 1994, 24:91-99.
401. Verset G., Verslype C., Reynaert H., Borbath I., Langlet P., Vandebroek A., Peeters M., Houbiers G., Francque S., Arvanitakis M., van Laethem J.L. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Brit. J. Cancer 2007, 97:582-588.
402. Vezzosi D., Bennet A., Rochaix P., Courbon F., Selves J., Pradere B., Buscail L., Susini C., Caron P. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sstS antibodies. Eur. J. Endocrinol. 2005, 152:757-767.
403. Vidal S., Oliveira M.C., Kovacs K., Scheithauer B.W., Lloyd R. Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell Tissue Res. 2000, 300:83-88.
404. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., Tuppurainen K., Ebeling T.M.L., Salmela P.I., Paschke R., Gundogdu S., De Menis E., Makinen M.J., Launonen V., Karhu A., Aaltonen L.A. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
405. Villard L., Romer A., Marincek N., Brunner P., Koller M.T., Schindler C., Ng Q.K., Mäcke H.R., Müller-Brand J., Rochlitz C., Briel M., Walter M.A. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 2012, 30:1100-1106.
406. Viollet C., Vaillend C., Videau C., Bluet-Pajot M.T., Ungerer A., L'Heritier A., Kopp C., Potier B., Billard J.M., Schaeffer J., Smith R.G., Rohrer S.P., Wilkinson H., Zheng H., Epelbaum J. Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur. J. Neurosci. 2000, 12:3761-3770.
407. Virgolini I., Leimer M., Handmaker H., Lastoria S., Bischof C., Muto P., Pangerl T., Gludovacz D., Peck-Radosavljevic M., Lister-James J., Hamilton G., Kaserer K., Valent P., Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998, 58:1850-1859.
408. Virgolini I., Patri P., Novotny C., Traub T., Leimer M., Füger B., Li S.R., Angelberger P., Raderer M., Wogritsch S., Kurtaran A., Kletter K., Dudczak R. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol. 2001, 12(Suppl. 2):S41-S45.
409. Waldherr C., Pless M., Maecke H.R., Haldemann A., Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol. 2001, 12:941-945.
410. Warnet A., Timsit J., Chanson P., Guillausseau P.J., Zamfirescu F., Harris A.G., Derome P., Cophignon J., Lubetzki J. The effect of somatostatin analog on chiasmal dysfunction from pituitary macroadenomas. J. Neurosurg. 1989, 71:687-690.
411. Weckbecker G., Briner U., Lewis I., Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002, 143:4123-4130.
412. Weckbecker G., Lewis I., Albert R., Schmid H.A., Hoyer D., Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2003, 2:999-1017.
413. Weckbecker G., Tolcsvai L., Stolz B., Pollak M. Somatostatin analog octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res. 1994, 54:6334-6337.
414. Wester H.J., Schottelius M., Poethko T., Bruus-Jensen K., Schwaiger M. Radiolabeled carbohydrated somatostatin analogs: a review of the current status. Cancer Biother. Radiopharm. 2004, 19:231-244.
415. Wester H.J., Schottelius M., Scheidhauer K., Meisetschläger G., Herz M., Rau F.C., Reubi J.C., Schwaiger M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imag. 2003, 30:117-122.
416. Wild D., Fani M., Behe M., Brink I., Rivier J.E., Reubi J.C., Maecke H.R., Weber W.A. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J. Nucl. Med. 2011, 52:1412-1417.
417. Wild D., Schmitt J.S., Ginj M., Mäcke H.R., Bernard B.F., Krenning E., de Jong M., Wenger S., Reubi J.C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imag. 2003, 30:1338-1347.
418. Wilkinson G.F., Feniuk W., Humphrey P.P.A. Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism. Brit. J. Pharmacol. 1997, 121:91-96.
419. 2+ and inositol 1,4,5-trisphosphate in CHO-K1 cells expressing human recombinant somatostatin sst5 receptors. Eur. J. Pharmacol. 1997, 340:277-285.
420. Wood D.F., Docherty K., Ramsden D.B., Sheppard M.C. A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro. Mol. Cell. Endocrinol. 1987, 52:257-261.
421. Wymenga A.N.M., Eriksson B., Salmela P.I., Jacobsen M.B., Van Cutsem E.J.D.G., Fiasse R.H., Valimaki M.J., Renstrup J., de Vries E.G.E., Oberg K.E. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol. 1999, 17:1111-1117.
422. Yamada Y., Post S.R., Wang K., Tager H.S., Bell G.I., Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:251-255.
423. Yamada Y., Reisine T., Law S.F., Ihara Y., Kubota A., Kagimoto S., Seino M., Seino Y., Bell G.I., Seino S. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human Sstr3, A Protein Coupled to Adenylyl Cyclase. Mol. Endocrinol. 1992, 6:2136-2142.
424. Yamashita N., Shibuya N., Ogata E. Hyperpolarization of the membrane-potential caused by somatostatin in dissociated human pituitary-adenoma cells that secrete growth hormone. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:6198-6202.
425. + currents in GH3 cells through activation of multiple somatostatin receptors. Endocrinology 2005, 146:4975-4984.
426. Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O'Dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A., Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 2010, 28:69-76.
427. Yao J.C., Phan A.T., Chang D.Z., Wolff R.A., Hess K., Gupta S., Jacobs C., Mares J.E., Landgraf A.N., Rashid A., Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008, 26:4311-4318.
428. Yasuda K., Rensdomiano S., Breder C.D., Law S.F., Saper C.B., Reisine T., Bell G.I. Cloning of a novel somatostatin receptor, Sstr3, coupled to adenylyl cyclase. J. Biol. Chem. 1992, 267:20422-20428.
429. + channels by isolated GK-protein in clonal rat anterior-pituitary cell-membranes. Mol. Endocrinol. 1987, 1:283-289.
430. Yen S.C., Siler T.M., Devane G.W. Effect of somatostatin in patients with acromegaly: suppression of growth-hormone, prolactin, insulin and glucose levels. N. Eng. J. Med. 1974, 290:935-938.
431. Yu J.H., Zhang Y.T., McIlroy J., Rordorf-Nikolic T., Orr G.A., Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3 '-kinase: stabilization and inhibition of the p110 alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 1998, 18:1379-1387.
432. Zambre Y., Ling Z.D., Chen M.C., Hou X., Woon C.W., Culler M., Taylor J.E., Coy D.H., Van Schravendijk C., Schuit F., Pipeleers D.G., Eizirik D.L. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem. Pharmacol. 1999, 57:1159-1164.
433. Zatelli M.C., Minoia M., Filieri C., Tagliati F., Buratto M., Ambrosio M.R., Lapparelli M., Scanarini M., degli Uberti E. Effect of everolimus on cell viability in non-functioning pituitary adenomas. J. Clin. Endocrinol. Metabol. 2010, 95:968-976.
434. Zatelli M.C., Minoia M., Martini C., Tagliati F., Ambrosio M.R., Schiavon M., Buratto M., Calabrese F., Gentilin E., Cavallesco G., Berdondini L., Rea F., degli Uberti E. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer 2010, 17:719-729.
435. Zatelli M.C., Piccin D., Tagliati F., Ambrosio M.R., Margutti A., Padovani R., Scanarini M., Culler M.D., degli Uberti E. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J. Clin. Endocrinol. Metabol. 2003, 88:2797-2802.
436. Zatelli M.C., Piccin D., Vignali C., Tagliati F., Ambrosio M.R., Bondanelli M., Cimino V., Bianchi A., Schmid H.A., Scanarini M., Pontecorvi A., De Marinis L., Maira G., gli Uberti E. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 2007, 14:91-102.